Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Expands By 2,262.6%

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 98,734 shares, an increase of 2,262.6% from the November 30th total of 4,179 shares. Based on an average trading volume of 170,340 shares, the days-to-cover ratio is currently 0.6 days. Based on an average trading volume of 170,340 shares, the days-to-cover ratio is currently 0.6 days.

Fresenius SE & Co. Trading Up 0.8%

Shares of OTCMKTS:FSNUY opened at $14.40 on Friday. The firm has a fifty day moving average of $14.83 and a two-hundred day moving average of $13.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 0.99. Fresenius SE & Co. has a 12-month low of $8.58 and a 12-month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The business had revenue of $6.29 billion for the quarter, compared to the consensus estimate of $6.38 billion. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.72%. Equities analysts predict that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on FSNUY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.